I don’t think the results would be any better for wockhardt…
Only reason it’s running is some sort of comments on WCK-5222 phase 3 …
No doubt in past wockhardt management has guided the phase 3 completion and launch in FY25…but any positive outcomes can also pre-empt the launch early as this drug is very important (even for USFDA)…
These are my personal views …
Disclosure: Holding and tracking developments
| Subscribe To Our Free Newsletter |
